(SDAX, Technology, SMHN GR)



Buy EUR 67.00		Value Indicators: DCF: FCF-Value Potential 26e:	EUR 67.00 40.00		4.0 5.0 3.0	Description: Leading solution provider for markets advanced packaging integration, LED, MEMS	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2025e
		Market cap:	802.9	Freefloat	100.00 %	Beta:	1.2
Price	EUR 42.00	No. of shares (m):	19.1	Kempen	9.90 %	Price / Book:	2.4 x
Upside	59.5 %	EV:	668.8	Teslin	7.50 %	Equity Ratio:	61 %
		Freefloat MC:	802.9	Henderson	5.00 %		
		Ø Trad. Vol. (30d):	2.69 m	JP Morgan	3.20 %		

Near-term uncertainty but mid-term prospects offer significant valuation upside

Meeting Highlights

- Against the background of the US tariffs, customers are likely to have taken a wait-and-see approach since early April, which leads to the assumption that Q2 orders will not exceed the Q1 level. It is likely, however, that there will be some catch-up effects in H2 with more clarity on the US tariff scheme as Europe might accept a 10% flat tariff according to recent press reports. In light of the generally elevated uncertainty, we have reduced our order backlog forecast by EUR 25m to just below EUR 310m at year-end.
- There is already high customer interest in the renewed mid-end cleaning solution with some unique technologies positioned below its high-end EUV tool. The product-launch appears to be on track with a pilot tool to be introduced by year-end and a serial tool during 2026. We expect the potential sales contribution of this tool to be a mid-double-digit million, which could offset a potential decline in demand from Chinese customers, which was at elevated levels in the recent past. There is expected to be significant replacement demand across the customer base.
- The equipping of the new Taiwanese production site is proceeding slightly ahead of schedule, the production ramp should commence as planned. This should provide some margin tailwind next year (50-100bps) with rising efficiency and the phase-out of costs for the existing sites.
- Mid-term growth prospects remain intact as rising package complexity and 3D structures drive rising demand for advanced packaging solutions coupled with further growth fueled by new applications. Besides the new mid-end photomask cleaning solution, (MEMS) wafer cleaning and hybrid bonding remain prominent growth drivers. All of these solutions are likely to generate initial orders in 2026 with the volume ramp to take place in 2027, underpinning the expectation of a return to growth in the not too distant future.

Conclusion


The investment case is considered to be largely unchanged. Near-term sentiment might remain subdued with uncertainty regarding current order intake, which will result in 2026 shaping up as a transition year with (WRe) a mid-single-digit sales decline. However, with two if not three new applications / solutions nearing market launch and initial order intake, there is decent visibility on growth drivers, which should enable SUSS to return to ~ double-digit growth from 2027 onwards. We expect SUSS to reiterate its ambition for ~ EUR 700-750m in sales by 2030, which translates into a >10% CAGR past 2026 and provides a basis for further margin expansion to WRe ~20% (EBIT). The upcoming CMD in November should help to look beyond the transition year 2026 and could hence serve as a catalyst owing to the significant valuation upside.

Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2025e (old)	+ / -	2026e (old)	+ / -	2027e (old)	+/-	 End of 2025 order backlog assumption reduced by EUR 25m owing to near-term uncertainties, which results in ~5% lower 2026 sales estimate
Sales EBIT	495.0 74.8	0.0 % 0.0 %	490.0 72.5	-5.1 % -9.9 %	539.0 88.6	-1.7 % -2.2 %	 Impact on 2027 forecasts is only negligible as most of the growth should be driven by new solutions such as photomask + wafer cleaning / hybrid bonding. An upcoming CMD should underpin such a scenario.

70- 11 the provent	FY End: 31.12. in EUR m	CAGR (24-27e)	2021	2022	2023	2024	2025e	2026e	2027e
es with	Sales	5.9 %	263.4	299.1	304.3	446.1	495.0	465.0	530.0
60 Vi your John Com	Change Sales yoy		4.5 %	13.6 %	1.7 %	46.6 %	10.9 %	-6.1 %	14.0 %
55	Gross profit margin		35.8 %	36.8 %	34.1 %	40.0 %	38.7 %	40.0 %	40.2 %
50 - Warden M	EBITDA	4.6 %	29.6	41.9	34.7	83.0	82.4	73.2	94.9
45 -	Margin		11.2 %	14.0 %	11.4 %	18.6 %	16.6 %	15.7 %	17.9 %
40 -	EBIT	1	22.6	32.8	27.8	75.1	74.8	65.3	86.7
35 - Ny N	Margin	17 0 01	8.6 %	11.0 %	9.1 %	16.8 %	15.1 %	14.0 %	16.4 %
30 -	Net income	-17.9 %	16.0	24.5	4.7	110.3	54.0	47.3	61.1
25 - 07/24 09/24 11/24 01/25 03/25 05/25	EPS	-17.8 %	0.84	1.28	0.25	5.77	2.82	2.48	3.20
SUSS MicroTec - SDAX (normalised)	EPS adj.	5.6 %	0.84	1.28	0.91	2.72	2.82	2.48	3.20
SUSS MicroTec — SDAX (normalised)	DPS	18.6 %	0.16	0.20	0.20	0.30	0.40	0.40	0.50
Rel. Performance vs SDAX:	Dividend Yield		0.7 %	1.3 %	0.9 %	0.6 %	1.0 %	1.0 %	1.2 %
	FCFPS		0.77	0.84	0.41	1.36	0.98	3.05	2.99
1 month: 4.4 %	FCF / Warket cap		3.2 %	5.6 %	1.8 %	2.7 %	2.3 %	7.3 %	7.1 %
6 months: -36.9 %	EV / Sales		1.6 x	0.8 x	1.3 x	1.8 x	1.4 x	1.3 x	1.1 x
Year to date: -35.3 %	EV / EBITDA		14.5 x	6.0 x	11.5 x	9.9 x	8.1 x	8.4 x	6.0 x
Trailing 12 months: -43.5 %	EV / EBIT		19.1 x	7.6 x	14.3 x	11.0 x	8.9 x	9.5 x	6.6 x
	P/E		28.6 x	11.7 x	89.7 x	8.6 x	14.9 x	16.9 x	13.1 x
Company events:	P / E adj.	-10.3 %	28.6 x	11.7 x	24.6 x	18.2 x	14.9 x	16.9 x	13.1 x
07.08.25 Q2	FCF Potential Yield		5.4 %	12.4 %	2.0 %	6.5 %	8.2 %	7.8 %	11.3 %
06.11.25 Q3	Net Debt		-28.4	-36.3	-31.2	-121.1	-134.1	-184.8	-234.4
	ROCE (NOPAT)		13.0 %	18.3 %	11.9 %	33.0 %	29.9 %	24.4 %	33.1 %
	Guidance: 2	2025: Sales El	JR 470 - 510	0m; EBIT ma	rgin 15-17%				

Analyst **Malte Schaumann** mschaumann@warburg-research.com +49 40 309537-170






Company Background

- Globally leading manufacturer of systems for the MEMS, advanced packaging, 3D IC and AI niche markets with the product segments lithography (mask aligner,coater), bonder and equipment to clean photomasks.
- MEMS integrate electronic and mechanical components.
- Advanced packaging is a special packaging process used as an alternative to the classic wire bonding ("flip chip") for semiconductors
 where these are directly bonded to the substrate without wire connections.
- 3D packaging is a solution to the increasingly difficult ongoing structural downsizing of semiconductors, which is e.g. used in AI related ICs. This market offers enormous growth potential for SÜSS.
- The majority of production is located at three sites (Garching, Sternenfels, Taiwan) which offer ample capacity for anticipated growth.
 SÜSS has ca. 1100 employees.

Competitive Quality

- SUSS consistently focuses on the core topics (precision, reliability and low total cost of ownership) in all segments and gears the products to the customers' needs.
- The 75-year company history and the consistently high product quality have firmly established SÜSS as a brand-name in the addressed markets.
- This and the global service network make the company a preferred supplier for production equipment in particular.
- As the respective markets have a niche character, SÜSS usually only has to face moderate competition and rarely has to compete with the major suppliers of the sector.
- This combined with the high product complexity poses a major barrier to market entry and secures the company a leading position in the respective markets.





DCF model														
	Detaile	d forecas	t period				٦	ransitior	al period					Term. Value
Figures in EUR m	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	
Sales	495.0	465.0	530.0	583.0	641.3	699.0	734.0	770.7	809.2	841.6	875.2	892.7	910.6	
Sales change	10.9 %	-6.1 %	14.0 %	10.0 %	10.0 %	9.0 %	5.0 %	5.0 %	5.0 %	4.0 %	4.0 %	2.0 %	2.0 %	2.0 %
EBIT	74.8	65.3	86.7	104.9	121.8	139.8	146.8	154.1	161.8	168.3	175.0	178.5	182.1	
EBIT-margin	15.1 %	14.0 %	16.4 %	18.0 %	19.0 %	20.0 %	20.0 %	20.0 %	20.0 %	20.0 %	20.0 %	20.0 %	20.0 %	
Tax rate (EBT)	30.2 %	30.3 %	29.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	
NOPAT	52.2	45.5	61.1	75.0	87.1	100.0	105.0	110.2	115.7	120.3	125.2	127.7	130.2	
Depreciation	7.6	7.9	8.2	11.4	12.8	14.0	14.7	15.4	16.2	16.8	17.5	17.9	18.2	
in % of Sales	1.5 %	1.7 %	1.5 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	2.9	-14.1	1.1	17.4	16.3	16.2	9.8	10.3	10.8	9.1	9.4	4.9	5.0	
- Capex	30.0	11.0	11.0	23.4	14.7	15.4	15.4	16.2	17.0	17.7	18.4	18.7	19.1	
Capex in % of Sales	6.1 %	2.4 %	2.1 %	2.3 %	2.3 %	2.2 %	2.1 %	2.1 %	2.1 %	2.1 %	2.1 %	2.1 %	2.1 %	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	26.9	56.5	57.2	45.6	68.9	82.4	94.4	99.2	104.1	110.4	114.9	121.9	124.3	127
PV of FCF	25.8	49.7	46.0	33.5	46.4	50.8	53.2	51.1	49.1	47.7	45.4	44.1	41.1	576
share of PVs		10.48 %						39.8	7 %					49.65 %
Model parameter							Valuat	ion (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 2	037e	58	34			
							Termin	al Value		57	76			
Debt ratio	1.00 %		Financial S	Strength		1.10	Financ	al liabilitie	s	1	13			
Cost of debt (after tax)	2.9 %		Liquidity (s	share)		1.10	Pensio	n liabilities	i		2			
Market return	8.25 %		Cyclicality			1.40	Hybrid	capital			0			
Risk free rate	2.75 %		Transpare	ncy		1.10	Minorit	y interest			0			
			Others			1.30	Market	val. of inv	estments		0			

Sensitivity Value per Share (EUR)

WACC

		Terminal C	Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.38	10.3 %	56.78	57.40	58.05	58.74	59.48	60.26	61.10	1.38	10.3 %	54.18	55.70	57.22	58.74	60.27	61.79	63.31
1.29	9.8 %	60.26	60.99	61.77	62.60	63.48	64.42	65.44	1.29	9.8 %	57.72	59.35	60.97	62.60	64.22	65.85	67.47
1.25	9.5 %	62.16	62.96	63.81	64.72	65.69	66.73	67.85	1.25	9.5 %	59.68	61.36	63.04	64.72	66.40	68.09	69.77
1.20	9.3 %	64.19	65.06	66.00	67.00	68.07	69.22	70.46	1.20	9.3 %	61.77	63.51	65.26	67.00	68.74	70.48	72.23
1.15	9.0 %	66.35	67.31	68.34	69.44	70.62	71.90	73.27	1.15	9.0 %	64.02	65.83	67.63	69.44	71.25	73.06	74.86
1.11	8.8 %	68.66	69.72	70.85	72.07	73.38	74.79	76.32	1.11	8.8 %	66.44	68.31	70.19	72.07	73.95	75.82	77.70
1.02	8.3 %	73.80	75.08	76.47	77.97	79.59	81.35	83.27	1.02	8.3 %	71.87	73.90	75.93	77.97	80.00	82.04	84.07

1.20

Liquidity

Equity Value

136

1,281

No. of shares (m)

Value per share (EUR)

19.1

67.00

Growth estimates mirror 10% CAGR past 2026

9.29 %

Beta

Sustainable EBIT margin of 20% anticipated



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m		2021	2022	2023	2024	2025e	2026e	2027e
Net Income before minorities		16.0	24.5	4.7	110.3	54.0	47.3	61.1
+ Depreciation + Amortisation		7.1	9.1	6.9	7.8	7.6	7.9	8.2
- Net Interest Income		-0.5	-0.3	0.5	2.8	1.8	1.8	0.0
 Maintenance Capex 		2.8	2.9	3.0	4.0	5.0	5.0	5.0
+ Other		2.6	0.0	0.0	-58.0	0.0	0.0	0.0
= Free Cash Flow Potential		23.3	31.0	8.1	53.4	54.8	48.4	64.3
FCF Potential Yield (on market EV)		5.4 %	12.4 %	2.0 %	6.5 %	8.2 %	7.8 %	11.3 %
WACC		9.29 %	9.29 %	9.29 %	9.29 %	9.29 %	9.29 %	9.29 %
= Enterprise Value (EV)		430.1	249.4	397.2	824.9	668.8	618.1	568.5
= Fair Enterprise Value		251.2	334.0	86.8	575.3	589.9	521.5	692.8
- Net Debt (Cash)		-122.9	-122.9	-122.9	-122.9	-135.9	-186.6	-236.2
- Pension Liabilities		1.8	1.8	1.8	1.8	1.8	1.8	1.8
- Other		0.0	0.0	0.0	0.0	0.0	0.0	0.0
 Market value of minorities 		0.0	0.0	0.0	0.0	0.0	0.0	0.0
 Market value of investments 		0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation		372.3	455.2	208.0	696.4	724.0	706.3	927.2
Number of shares, average		19.1	19.1	19.1	19.1	19.1	19.1	19.1
= Fair value per share (EUR)		19.48	23.81	10.88	36.43	37.87	36.95	48.50
premium (-) / discount (+) in %						-9.8 %	-12.0 %	15.5 %
Sensitivity Fair value per Share (E	UR)							
1:	2.29 %	16.27	19.54	9.77	29.08	30.34	30.29	39.65
1	1.29 %	17.15	20.71	10.07	31.10	32.40	32.11	42.08
1	0.29 %	18.20	22.11	10.44	33.50	34.87	34.29	44.98
WACC	9.29 %	19.48	23.81	10.88	36.43	37.87	36.95	48.50
	8.29 %	21.06	25.92	11.43	40.06	41.60	40.24	52.88
	7.29 %	23.08	28.61	12.13	44.69	46.34	44.44	58.45
	6.29 %	25.75	32.15	13.05	50.79	52.60	49.97	65.80

Increasing sales and margins result in higher value indications in coming years



Valuation							
	2021	2022	2023	2024	2025e	2026e	2027e
Price / Book	2.9 x	1.6 x	2.4 x	3.4 x	2.4 x	2.2 x	1.9 x
Book value per share ex intangibles	6.95	8.01	7.98	13.42	15.94	18.02	20.82
EV / Sales	1.6 x	0.8 x	1.3 x	1.8 x	1.4 x	1.3 x	1.1 x
EV / EBITDA	14.5 x	6.0 x	11.5 x	9.9 x	8.1 x	8.4 x	6.0 x
EV / EBIT	19.1 x	7.6 x	14.3 x	11.0 x	8.9 x	9.5 x	6.6 x
EV / EBIT adj.*	19.1 x	8.3 x	14.3 x	11.0 x	8.9 x	9.5 x	6.6 x
P / FCF	31.2 x	17.8 x	54.1 x	36.5 x	43.0 x	13.8 x	14.0 x
P/E	28.6 x	11.7 x	89.7 x	8.6 x	14.9 x	16.9 x	13.1 x
P / E adj.*	28.6 x	11.7 x	24.6 x	18.2 x	14.9 x	16.9 x	13.1 x
Dividend Yield	0.7 %	1.3 %	0.9 %	0.6 %	1.0 %	1.0 %	1.2 %
FCF Potential Yield (on market EV)	5.4 %	12.4 %	2.0 %	6.5 %	8.2 %	7.8 %	11.3 %
*Adjustments made for: -							

Company Specific Items							
	2021	2022	2023	2024	2025e	2026e	2027e
Order entry	335.6	410.9	420.5	423.3	375.0	0.0	0.0
Order backlog	193.3	346.4	452.5	428.0	0.0	0.0	0.0

COMMENT Published 17.06.2025 5

Consolidated profit and loss


<u> </u>	WARBURG
/ V V	RESEARCH

In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Sales	263.4	299.1	304.3	446.1	495.0	465.0	530.0
Change Sales yoy	4.5 %	13.6 %	1.7 %	46.6 %	10.9 %	-6.1 %	14.0 %
COGS	169.2	189.1	200.4	267.8	303.2	279.2	316.8
Gross profit	94.2	110.1	103.9	178.3	191.8	185.8	213.2
Gross margin	35.8 %	36.8 %	34.1 %	40.0 %	38.7 %	40.0 %	40.2 %
Research and development	22.1	25.0	31.3	40.1	45.0	46.5	48.0
Sales and marketing	24.9	28.5	21.4	27.5	32.0	33.0	35.0
Administration expenses	22.9	23.3	24.2	34.0	38.0	39.0	41.0
Other operating expenses	5.9	12.2	6.5	6.1	2.0	2.0	2.5
Other operating income	4.2	11.8	7.3	4.5	0.0	0.0	0.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	29.6	41.9	34.7	83.0	82.4	73.2	94.9
Margin	11.2 %	14.0 %	11.4 %	18.6 %	16.6 %	15.7 %	17.9 %
Depreciation of fixed assets	6.4	8.1	5.3	6.2	6.6	6.9	7.2
EBITA	23.2	33.8	29.3	76.7	75.8	66.3	87.7
Amortisation of intangible assets	0.7	1.0	1.5	1.6	1.0	1.0	1.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	22.6	32.8	27.8	75.1	74.8	65.3	86.7
Margin	8.6 %	11.0 %	9.1 %	16.8 %	15.1 %	14.0 %	16.4 %
EBIT adj.	22.6	30.0	27.8	75.1	74.8	65.3	86.7
Interest income	0.0	0.3	1.0	3.2	2.0	2.0	0.2
Interest expenses	0.5	0.6	0.4	0.5	0.2	0.2	0.2
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	22.1	32.5	28.3	77.9	76.6	67.1	86.7
Margin	8.4 %	10.9 %	9.3 %	17.5 %	15.5 %	14.4 %	16.4 %
Total taxes	6.1	8.0	11.0	25.8	22.6	19.8	25.6
Net income from continuing operations	16.0	24.5	17.3	52.1	54.0	47.3	61.1
Income from discontinued operations (net of tax)	0.0	0.0	-12.6	58.3	0.0	0.0	0.0
Net income before minorities	16.0	24.5	4.7	110.3	54.0	47.3	61.1
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	16.0	24.5	4.7	110.3	54.0	47.3	61.1
Margin	6.1 %	8.2 %	1.6 %	24.7 %	10.9 %	10.2 %	11.5 %
Number of shares, average	19.1	19.1	19.1	19.1	19.1	19.1	19.1
EPS	0.84	1.28	0.25	5.77	2.82	2.48	3.20
EPS adj.	0.84	1.28	0.91	2.72	2.82	2.48	3.20
*Adjustments made for:							


Guidance: 2025: Sales EUR 470 - 510m; EBIT margin 15-17%

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
	2021	2022	2023	2024	2025e	2020e	20276
Total Operating Costs / Sales	27.2 %	25.8 %	25.0 %	23.1 %	23.6 %	25.9 %	23.9 %
Operating Leverage	2.3 x	3.4 x	-8.9 x	3.7 x	0.0 x	2.1 x	2.3 x
EBITDA / Interest expenses	63.5 x	74.2 x	82.9 x	178.0 x	411.8 x	366.1 x	474.6 x
Tax rate (EBT)	27.5 %	24.6 %	38.8 %	33.2 %	29.5 %	29.5 %	29.5 %
Dividend Payout Ratio	19.1 %	15.6 %	22.1 %	11.0 %	14.2 %	16.2 %	15.6 %
Sales per Employee	237,760	248,246	237,334	329,990	755,725	709,924	809,160



Performance per Share



COMMENT Published 17.06.2025


L'Istad bol ~




Consolidated balance sheet							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Assets							
Goodwill and other intangible assets	24.0	24.6	24.1	23.2	23.2	23.2	23.2
thereof other intangible assets	5.6	5.9	5.5	4.5	4.5	4.5	4.5
thereof Goodwill	18.4	18.6	18.5	18.6	18.6	18.6	18.6
Property, plant and equipment	44.5	48.9	31.1	33.8	56.2	59.3	62.1
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	68.5	73.4	55.2	57.1	79.5	82.6	85.4
Inventories	99.5	150.5	166.7	214.0	206.3	193.8	200.0
Accounts receivable	47.4	57.0	52.9	73.8	81.4	76.4	87.1
Liquid assets	52.1	61.3	48.0	136.2	149.4	200.1	249.7
Other short-term assets	11.6	11.0	46.9	19.9	19.8	19.9	19.9
Current assets	210.7	279.8	314.5	443.8	457.0	490.2	556.6
Total Assets	279.2	353.3	369.7	500.9	536.4	572.7	642.0
Liabilities and shareholders' equity							
Subscribed capital	19.1	19.1	19.1	19.1	19.1	19.1	19.1
Capital reserve	135.0	156.5	157.3	262.4	262.4	262.4	262.4
Retained earnings	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other equity components	2.8	2.2	0.2	-1.8	46.5	86.1	139.6
Shareholders' equity	156.9	177.7	176.6	279.7	328.0	367.7	421.1
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	156.9	177.7	176.6	279.7	328.0	367.7	421.1
Provisions	11.2	11.8	10.6	9.9	9.9	9.9	9.9
thereof provisions for pensions and similar obligations	5.3	5.0	1.6	1.8	1.8	1.8	1.8
Financial liabilities (total)	18.3	20.0	15.2	13.3	13.5	13.5	13.5
Short-term financial liabilities	1.2	1.2	1.2	1.3	1.3	1.3	1.3
Accounts payable	24.4	27.1	27.1	31.5	33.9	25.5	36.3
Other liabilities	68.4	116.7	140.2	166.4	151.1	156.1	161.1
Liabilities	122.3	175.5	193.1	221.1	208.5	205.1	220.9
Total liabilities and shareholders' equity	279.2	353.3	369.7	500.9	536.4	572.7	642.0

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
Efficiency of Capital Employment							
Operating Assets Turnover	2.0 x	2.0 x	2.2 x	2.4 x	2.3 x	2.3 x	2.5 x
Capital Employed Turnover	2.1 x	2.1 x	2.1 x	2.8 x	2.6 x	2.5 x	2.8 x
ROA	23.4 %	33.4 %	8.6 %	193.4 %	67.9 %	57.3 %	71.6 %
Return on Capital							
ROCE (NOPAT)	13.0 %	18.3 %	11.9 %	33.0 %	29.9 %	24.4 %	33.1 %
ROE	10.9 %	14.7 %	2.7 %	48.4 %	17.8 %	13.6 %	15.5 %
Adj. ROE	10.9 %	14.7 %	9.8 %	22.8 %	17.8 %	13.6 %	15.5 %
Balance sheet quality							
Net Debt	-28.4	-36.3	-31.2	-121.1	-134.1	-184.8	-234.4
Net Financial Debt	-33.8	-41.3	-32.8	-122.9	-135.9	-186.6	-236.2
Net Gearing	-18.1 %	-20.4 %	-17.7 %	-43.3 %	-40.9 %	-50.3 %	-55.6 %
Net Fin. Debt / EBITDA	n.a.						
Book Value / Share	8.2	9.3	9.2	14.6	17.2	19.2	22.0
Book value per share ex intangibles	7.0	8.0	8.0	13.4	15.9	18.0	20.8



Book Value per Share



Published 17.06.2025 7

Consolidated cash flow statement




In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Net income	16.0	24.5	4.7	110.3	54.0	47.3	61.1
Depreciation of fixed assets	6.4	8.1	5.3	6.2	6.6	6.9	7.2
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.7	1.0	1.5	1.6	1.0	1.0	1.0
Increase/decrease in long-term provisions	-1.2	-0.5	-0.1	0.2	0.0	0.0	0.0
Other non-cash income and expenses	7.8	8.2	19.0	-23.7	-10.0	0.0	0.0
Cash Flow before NWC change	29.7	41.3	30.5	94.7	51.6	55.2	69.3
Increase / decrease in inventory	-29.5	-52.8	-29.4	-55.5	7.7	12.5	-6.2
Increase / decrease in accounts receivable	1.9	-11.1	0.2	-20.8	-7.6	5.0	-10.7
Increase / decrease in accounts payable	22.3	46.5	11.2	15.2	-2.9	-3.4	15.8
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-5.4	-17.4	-18.0	-61.2	-2.9	14.1	-1.1
Net cash provided by operating activities [1]	24.3	23.9	12.5	33.5	48.7	69.3	68.2
Investments in intangible assets	1.2	1.1	1.1	0.7	1.0	1.0	1.0
Investments in property, plant and equipment	8.5	10.5	10.5	9.1	29.0	10.0	10.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	69.5	0.0	0.0	0.0
Net cash provided by investing activities [2]	-9.6	-7.9	-4.6	62.0	-30.0	-11.0	-11.0
Change in financial liabilities	-3.8	-3.7	-3.4	1.6	0.2	0.0	0.0
Dividends paid	0.0	-3.1	-3.8	-3.8	-5.7	-7.6	-7.6
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	-3.8	-6.8	-7.2	-2.2	-5.5	-7.6	-7.6
Change in liquid funds [1]+[2]+[3]	10.9	9.3	0.7	93.2	13.2	50.7	49.6
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	51.7	61.3	52.0	131.4	149.4	200.1	249.7

Financial Ratios


	2021	2022	2023	2024	2025e	2026e	2027e
Cash Flow							
FCF	14.7	16.0	7.9	25.9	18.7	58.3	57.2
Free Cash Flow / Sales	5.6 %	5.4 %	2.6 %	5.8 %	3.8 %	12.5 %	10.8 %
Free Cash Flow Potential	23.3	31.0	8.1	53.4	54.8	48.4	64.3
Free Cash Flow / Net Profit	91.9 %	65.4 %	167.2 %	23.5 %	34.6 %	123.2 %	93.6 %
Interest Received / Avg. Cash	0.0 %	0.5 %	1.7 %	3.5 %	1.4 %	1.1 %	0.1 %
Interest Paid / Avg. Debt	2.4 %	2.9 %	2.4 %	3.3 %	1.5 %	1.5 %	1.5 %
Management of Funds							
Investment ratio	3.7 %	3.9 %	3.8 %	2.2 %	6.1 %	2.4 %	2.1 %
Maint. Capex / Sales	1.1 %	1.0 %	1.0 %	0.9 %	1.0 %	1.1 %	0.9 %
Capex / Dep	136.4 %	127.6 %	169.0 %	125.4 %	394.7 %	139.2 %	134.1 %
Avg. Working Capital / Sales	33.0 %	32.0 %	34.2 %	29.3 %	31.8 %	32.6 %	27.4 %
Trade Debtors / Trade Creditors	194.0 %	210.3 %	195.2 %	233.8 %	240.1 %	299.6 %	239.9 %
Inventory Turnover	1.7 x	1.3 x	1.2 x	1.3 x	1.5 x	1.4 x	1.6 x
Receivables collection period (days)	66	70	63	60	60	60	60
Payables payment period (days)	53	52	49	43	41	33	42
Cash conversion cycle (Days)	155	157	159	172	153	149	128

2024 2025e 2026e

CAPEX and Cash Flow in EUR m



Working Capital



COMMENT

Published 17.06.2025

2027e

8

Free Cash Flow Generation



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- -4 MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
SUSS MicroTec	5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A1K0235.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	141	70
Hold	49	24
Sell	6	3
Rating suspended	5	2
Total	201	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	36	72
Hold	10	20
Sell	1	2
Rating suspended	3	6
Total	50	100

PRICE AND RATING HISTORY SUSS MICROTEC AS OF 17.06.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280	Hannes Müller	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier	mheider@warburg-research.com +49 40 309537-270	Software, IT Andreas Pläsier	+49 40 309537-246
Head of Research	hrueschmeier@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Stefan Augustin	+49 40 309537-168	Malte Schaumann	+49 40 309537-170
Cap. Goods, Engineering Jan Bauer	saugustin@warburg-research.com +49 40 309537-155	Technology Oliver Schwarz	mschaumann@warburg-research.com +49 40 309537-250
Renewables	jbauer@warburg-research.com	Chemicals, Agriculture	oschwarz@warburg-research.com
Christian Cohrs	+49 40 309537-175	Simon Stippig	+49 40 309537-265
Industrials & Transportation	ccohrs@warburg-research.com	Real Estate, Telco	sstippig@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Felix Ellmann	+49 40 309537-120	Robert-Jan van der Horst	+49 40 309537-290
Software, IT	fellmann@warburg-research.com	Technology	rvanderhorst@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
Marius Fuhrberg	+49 40 309537-185	,	j
Financial Services	mfuhrberg@warburg-research.com		
Fabio Hölscher Automobiles, Car Suppliers	+49 40 309537-240 fhoelscher@warburg-research.com		
Philipp Kaiser	+49 40 309537-260		
Real Estate, Construction	pkaiser@warburg-research.com		
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com		
Klaus Schilling	+49 69 5050-7400	Sascha Propp	+49 40 3282-2656
Head of Equity Sales, Germany	kschilling@mmwarburg.com	France	spropp@mmwarburg.com
Tim Beckmann	+49 40 3282-2665		
United Kingdom	tbeckmann@mmwarburg.com		
Jens Buchmüller Scandinavia, Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com		
Matthias Fritsch	+49 40 3282-2696	Leyan Ilkbahar	+49 40 3282-2695
United Kingdom, Ireland	mfritsch@mmwarburg.com	Roadshow/Marketing	lilkbahar@mmwarburg.com
Rudolf Alexander Michaelis		Antonia Möller Roadshow/Marketing	+49 69 5050-7417
Germany Roman Alexander Niklas	rmichaelis@mmwarburg.com +49 69 5050-7412	Juliane Niemann	amoeller@mmwarburg.com +49 40 3282-2694
Switzerland, Poland, Italy	rniklas@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOR	RING
Oliver Merckel	+49 40 3282-2634	Sebastian Schulz	+49 40 3282-2631
Head of Sales Trading	omerckel@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Bastian Quast	+49 40 3282-2701	Jörg Treptow	+49 40 3282-2658
Sales Trading Christian Salomon	bquast@mmwarburg.com +49 40 3282-2685	Designated Sponsoring	jtreptow@mmwarburg.com
Sales Trading	csalomon@mmwarburg.com		
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be fo	<u> </u>		cjaspernene@minwarburg.com
Warburg Research Bloomberg	research.mmwarburg.com/en/index.html RESP MMWA GO	LSEG Capital IQ	www.lseg.com www.capitaliq.com
FactSet	www.factset.com		www.capitaliq.com
. 45(66)			
Fan anana rissan sector			
For access please contac Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703